Kalaris Therapeutics, Inc. reported on its 2025 Annual Meeting held on August 12, 2025, where stockholders elected two directors and ratified Deloitte & Touche LLP as the accounting firm for 2025, with votes tallied as follows: Srinivas Akkaraju received 14,626,646 votes in favor, and Andrew Oxtoby received 14,668,424 votes in favor. The accounting firm's selection passed with 16,090,928 votes in favor.